MTOR and neoplasm: The identification of candidate inhibitors with novel mechanisms of action, the recognition of prognostic/predictive biomarkers, and the modeling and testing of rational, mTOR inhibition-based, combinatorial strategies endowed with highly synergistic anti-tumor activity will pave the way for a new generation of effective and personalized cancer treatments.